Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT study of angiotensin II to enhance liver radioembolization
NL-OMON59623Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Angiotensin II in liver cancer, hepatic neoplasm, sponsored by University Medical Center Utrecht. Started Jan 2026; status: recruiting.
02
Drugs
Angiotensin II
03
Conditions
liver cancerhepatic neoplasm
Beyond the preview
Go deeper on NL-OMON59623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59623.